Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Norgine clinical trials
Part of Goldman Sachs Asset Management, which holds majority as of 2022-12-15. Source
The registry lists 62 studies whose lead sponsor is Norgine or one of 1 company grouped under it. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 7, 2026.
Keep track of what changes. Save the Norgine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Norgine.
- Norgine54 studiesSame company
Something wrong?
- 8 studies →
Studies
Recruiting first, then most recently updated. Showing 50 of 62. Browse all 62 →
- A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for ColonoscopyRecruitingNCT07218523Phase 3
- Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell DiseaseRecruitingNCT06578507Phase 2
Sponsor listed in the registry: Theravia · First submitted before Theravia became part of Norgine
- A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Hydroxycarbamide in Healthy VolunteersCompletedNCT05025072Phase 1
Sponsor listed in the registry: Theravia · First submitted before Theravia became part of Norgine
- SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)CompletedNCT03806452Phase 2
Sponsor listed in the registry: Theravia · First submitted before Theravia became part of Norgine
- Study to Evaluate the Safety of Post-Operative TZP-101 (IV Ulimorelin) After Partial Bowel ResectionCompletedNCT01710982Phase 3
- Safety and Tolerability of the Twice Daily Intra-anal Application of NRL001 Cream for 14 DaysCompletedNCT06593730Phase 1
- PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)CompletedNCT00794716Phase 2
- The Safety and Dose Response to Single Anal Doses of NRL001CompletedNCT06593743Phase 1
- A Monocentric Study to Investigate a New Low Dose Oral Gut Cleansing SolutionCompletedNCT06597903Phase 2
- ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension StudyActive, not recruitingNCT04707235
Sponsor listed in the registry: Theravia · First submitted before Theravia became part of Norgine
- A Pharmacokinetic Study of PLENVU® in Healthy SubjectsCompletedNCT03437265Phase 1
- Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.CompletedNCT05470270Phase 2
Sponsor listed in the registry: Theravia · First submitted before Theravia became part of Norgine
- Real Word Evidence With 1L Polyethylene Glycol (PEG)+ Ascorbic Acid in IberiaCompletedNCT05174845
- Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)CompletedNCT02522104Phase 4
Sponsor listed in the registry: Theravia · First submitted before Theravia became part of Norgine
- European Sickle Cell Disease Cohort - HydroxyureaCompletedNCT02516579
Sponsor listed in the registry: Theravia · First submitted before Theravia became part of Norgine
- Plasma DNA and Vascular Remodelling in Patients With Sickle Cell DiseaseCompletedNCT02721472Not applicable
Sponsor listed in the registry: Theravia · First submitted before Theravia became part of Norgine
- Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin (PROSPER)CompletedNCT02488993
- Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.CompletedNCT02273167Phase 3
- Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in AdultsCompletedNCT02254486Phase 3
- Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only Dosing Regimen in Adults.CompletedNCT02273141Phase 3
- Performance of NER1008 Enema Compared With Fleet® Enema in Bowel CleansingCompletedNCT02468726Not applicable
- Sensitivity of Alternative NRL972 Detection Methods in Healthy SubjectsCompletedNCT01164332Phase 1
- A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment PeriodCompletedNCT01656720Phase 2
- A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)CompletedNCT01689792Phase 4
- Pharmacodynamic and Clinical Evaluation of Dose and Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using the Split-dosing Intake Regimen in Healthy Subjects and in Subjects Undergoing Screening ColonoscopyCompletedNCT01714466Phase 2
- Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux DiseaseCompletedNCT01493089Phase 3
- Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy SubjectsCompletedNCT01834742Phase 1
- A Clinical Investigation to Demonstrate the Performance of a New Enema (TF037) in Distal Bowel Cleansing Compared With Fleet EnemaCompletedNCT01715272Phase 1
- Effect of 7 Days of Dosing With a 10 mg Rectal Suppository of NRL001in Patients With Faecal IncontinenceCompletedNCT01175941Phase 1
- A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting ConditionsCompletedNCT01710995Phase 1
- Study to Examine the Effect of Ulimorelin on the Pharmacokinetics of Midazolam in Healthy VolunteersCompletedNCT01405612Phase 1
- Evaluation of the Pharmacokinetics of Ulimorelin in Subjects With Hepatic Impairment and Healthy SubjectsCompletedNCT01405599Phase 1
- Comparator Study of PEG 3350 Versus Prucalopride in Females With Chronic ConstipationCompletedNCT01251822Phase 3
- A Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery and Pharmacokinetics of 14C TZP-101CompletedNCT01668199Phase 1
- Evaluation of the Main Determinants of Patient Acceptability of the Bowel Cleansing Procedure, and of Success of Bowel Cleansing and Caecal IntubationCompletedNCT01626196
- Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy VolunteersCompletedNCT01406925Phase 1
- Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of 7.5, 10, 12.5 or 15 mg NRL001 in a 2 g Suppository for 14 DaysCompletedNCT01099670Phase 1
- Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of a Single Rectal Application of 10 mg NRL001 in Elderly SubjectsCompletedNCT01099683Phase 1
- Study to Assess the Tolerability, Safety and Efficacy of an Adapted Gut Cleansing Solution in Routine Colon Cleansing Prior to ColonoscopiesCompletedNCT01251237Phase 2
- Reproducibility of Child-Turcotte-Pugh (CTP) Rating and NRL972 Pharmacokinetics in Patients With CirrhosisCompletedNCT00896597Phase 1
- Constipation Associated With Irritable Bowel Syndrome (IBS-C)CompletedNCT00796354Phase 3
- Study to Investigate Safety and Response to 1 or 2 g Rectal Suppositories Containing 5 or 10 mg NRL001.CompletedNCT00857467Phase 1
- Effect of Chronic Viral Hepatitis on the Pharmacokinetics of NRL972.CompletedNCT00915057Phase 2
- Study of Escalating Doses of NRL001 Given in Slow-release Rectal Suppositories of Different WeightsCompletedNCT00850590Phase 1
- Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.CompletedNCT00794482Phase 3
- Scintigraphic Assessment Following Klean-Prep® or Moviprep®CompletedNCT00896246Phase 1
- Effect of Single Doses of 10 mg NRL001 Applied as a Suppository to the Anal Canal or RectumCompletedNCT00893607Phase 1
- Effects of Oral PEG 3350 on Electrolyte BalanceCompletedNCT00868985Phase 1
- Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and CloxacillinCompletedNCT00857480Phase 1
- Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy VolunteersCompletedNCT00856869Phase 1/2